Scientia Receives Investment to Support Interventional Neurovascular, PAD, and Oncology Devices

May 27, 2021—Scientia Vascular, a developer of microfabrication technology and products for the treatment of neurovascular disease, peripheral vascular disease, and interventional oncology, announced it has raised $50 million of growth equity financing from Vivo Capital, a health care investment firm.

According to the company, the financing will be used to accelerate sales, marketing, and new product development in both its core neurovascular stroke market as well as adjacent markets in peripheral vascular and interventional oncology. Scientia’s Aristotle guidewires for neurointerventional procedures are commercially available.

“We are excited to partner with Vivo as we embark on our next stage of growth,” commented John Lippert, Founder and Chief Executive Officer of Scientia, in the announcement, “We’ve had a long-standing vision for enhancing patient treatment, which now can be accelerated with the financing.”

Nathan Dau, Executive Director at Vivo Capital, added, “Scientia has been tremendously successful with limited resources since its commercial launch in 2018. The company recently received FDA approval for its Plato 17 microcatheter, which leverages Scientia’s microfabrication technology to enhance trackability, control, and stability. Vivo looks forward to helping the company continue to launch new products and expand globally.”